Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
February 2011

Lurasidone (Latuda)
The new antipsychotic lurasidone (Latuda) appears generally comparable in safety and efficacy to currently available agents.

Antipsychotics Increase the Risk of Venous Thromboembolism
Antipsychotics cause a small increase in the risk of venous thromboembolism in some patients.

Pramipexole for Cognitive Enhancement in Bipolar Disorder
In one study, adjunctive pramipexole (Mirapex and others) provided cognitive benefit for euthymic patients with bipolar disorder.

In Brief
Mindfulness-Based Cognitive Therapy Equivalent to Maintenance Antidepressant Treatment for Relapse Prevention; Docosahexaenoic Acid (DHA) Supplementation Does Not Slow Cognitive Decline in Patients with Alzheimer Disease

Anticonvulsants and Suicide Risk: The Saga Continues
A new study finds an increased risk of suicide in patients taking anticonvulsants for indications other than epilepsy but no additional risk in patients with epilepsy.

Lurasidone (Latuda)

February 2011

In October 2010, the US Food and Drug Administration (FDA) approved the new antipsychotic lurasidone (Latuda) to treat schizophrenia in adults. Lurasidone, manufactured by Sunovion, should be available in pharmacies in February 2011.

Lurasidone is an azapirone derivative and novel molecular…

To view the rest of this article, please: